Please Upload related files below
Fill in below.
Tell us the stocks you own using Snaptrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. Snaptrade only shares the tickers you own and your transaction history, not your account numbers. Using Snaptrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery- link your account with Snaptrade.
On August 6, 2019, the United States Food and Drug Administration (“FDA”) issued a statement revealing data manipulation in connection with the May 2019 approval of Novartis’ gene therapy drug, Zolgensma. According the the statement, AveXis Inc., a subsidiary of Novartis and the product’s manufacturer, “became aware of the issue of the data manipulation that created inaccuracies in their [biologics license application] before the FDA approved the product, yet did not inform the FDA until after the product was approved”. The FDA’s continuing investigation may lead to penalties for Novartis, and the Company’s share price has already fallen significantly.